

## *Drug Safety*

### **Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK**

Sieta T. de Vries, PhD<sup>1,2</sup>; Petra Denig, PhD<sup>1</sup>; Adriana Andrić, MD<sup>3,4</sup>; Marina Dimov Di Giusti, MD<sup>3,4</sup>; Alicia Ptaszynska-Neophytou<sup>5</sup>; Linda Härmark, PhD<sup>6</sup>; Peter G.M. Mol, PhD<sup>1,2,7</sup>; on behalf of IMI Web-RADR work package 3b consortium and SCOPE Joint Action work package 4.

<sup>1</sup> University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, The Netherlands

<sup>2</sup> Web-RADR work package 3B

<sup>3</sup> Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Croatia

<sup>4</sup> SCOPE Joint Action work package 4

<sup>5</sup> Medicines and Healthcare products Regulatory Agency, London, UK

<sup>6</sup> Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands

<sup>7</sup> Dutch Medicines Evaluation Board, Utrecht, the Netherlands

#### **Corresponding author:**

P.G.M. Mol, PhD

E-mail: p.g.m.mol@umcg.nl

Phone: +31 (0)50-3617861

Fax +31 (0)50-3617889

**Electronic Supplementary Material Table 2.** Number (%) of healthcare professionals selecting the different answer options for motives (not) to report adverse drug reactions and P-values for tests of differences across the countries

	Total	Croatia (HR)	Netherlands (NL)	UK	P-value
<b>A. What would motivate you to report an adverse drug reaction?<sup>1</sup></b>					
If you receive an award for the most informative report of the year	13 (4)	6 (3)	0 (0)	7 (11)	0.006 (V=0.18) HR-NL: 0.165 <b>NL-UK: 0.010</b> HR-UK: 0.017
If you receive financial compensation	25 (9)	13 (7)	3 (5)	9 (15)	0.137
If there is a legal obligation to report adverse drug reactions	150 (51)	114 (65)	13 (24)	23 (38)	<0.001 (V=0.34) <b>HR-NL: &lt;0.001</b> NL-UK: 0.102 <b>HR-UK: &lt;0.001</b>
If you strongly suspect there is an association of causality between the medicine and the reaction	261 (89)	160 (91)	47 (85)	54 (89)	0.503
If it concerns a reaction to a new, recently marketed medicine	226 (77)	127 (72)	44 (80)	55 (90)	0.013 (V=0.17) HR-NL: 0.247 NL-UK: 0.122 <b>HR-UK: 0.004</b>
If the medicine causing the adverse drug reaction has a black triangle in the package leaflet	96 (33)	47 (27)	2 (4)	47 (77)	<0.001 (V=0.52) <b>HR-NL: &lt;0.001</b> <b>NL-UK: &lt;0.001</b> <b>HR-UK: &lt;0.001</b>
If the medicine is taken for compassionate use	38 (13)	19 (11)	8 (15)	11 (18)	0.327
If the medicine was taken as offlabel use	119 (41)	67 (38)	22 (40)	30 (49)	0.312
If you prescribed the medicine yourself	72 (25)	46 (26)	6 (11)	20 (33)	0.019 (V=0.16) HR-NL: 0.018 <b>NL-UK: 0.005</b> HR-UK: 0.318
If the adverse drug reaction is severe/serious	251 (86)	148 (84)	48 (87)	55 (90)	0.477
If the adverse drug reaction influences a patient's daily activities	186 (64)	112 (64)	28 (51)	46 (75)	0.023 (V=0.16) HR-NL: 0.092 <b>NL-UK: 0.006</b> HR-UK: 0.093
If the adverse drug reaction lasts for a relatively long period (e.g. more than two/three days)	135 (46)	82 (47)	21 (38)	32 (52)	0.302
If the report is fully anonymous with respect to the patient it concerns	101 (35)	66 (38)	9 (16)	26 (43)	0.005 (V=0.19) <b>HR-NL: 0.003</b> <b>NL-UK: 0.002</b> HR-UK: 0.479
If the report is fully anonymous with respect to you as a reporter	35 (12)	24 (14)	1 (2)	10 (16)	0.031 (V=0.15) <b>HR-NL: 0.014</b>

					<b>NL-UK: 0.007</b> HR-UK: 0.597
<b>B. What are your reasons for not reporting an ADR?<sup>2</sup></b>					
Lack of time	155 (64)	94 (68)	32 (62)	29 (54)	0.166
Uncertainty about the drug causing the adverse drug reaction	108 (44)	50 (36)	29 (56)	29 (54)	0.015 (V=0.18) <b>HR-NL: 0.015</b> NL-UK: 0.831 HR-UK: 0.027
Difficulty in accessing reporting forms	67 (27)	35 (25)	16 (31)	16 (30)	0.698
Lack of understanding of the purpose of spontaneous reporting systems	14 (6)	6 (4)	3 (6)	5 (9)	0.421
If the adverse drug reaction has been resolved	30 (12)	14 (10)	5 (10)	11 (20)	0.122
If it concerns a well-known adverse drug reaction	154 (63)	73 (53)	44 (85)	37 (69)	<0.001 (V=0.26) <b>HR-NL: &lt;0.001</b> NL-UK: 0.051 HR-UK: 0.049
Serious reactions are already known at the time a drug is marketed	28 (11)	12 (9)	5 (10)	11 (20)	0.066
One case reported by an individual will not contribute to medical knowledge	2 (1)	1 (1)	1 (2)	0 (0)	0.538
If I think the case does not contribute to medical knowledge	25 (10)	11 (8)	10 (19)	4 (7)	0.055

---

<sup>1</sup> 3 missing; 1 'Nothing would motivate me'; <sup>2</sup> 48 'None'